Trial Profile
Open, Multicenter Phase II Study to Evaluate the Efficacy and Safety of the Combination of Panitumumab With Irinotecan in Patients With Wild-Type KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Irinotecan
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- Acronyms SPECTRA
- 31 Jul 2019 Results published in the British Journal of Cancer
- 11 Aug 2014 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
- 26 Mar 2014 Planned End Date changed from 1 Feb 2013 to 1 Aug 2014 as reported by ClonicalTrials.gov record.